CEACAM6 and Duodenal polyposis: Effect of the CEACAM6 antibody-drug conjugate on APCMin/+ mice can also be investigated, and if this shows therapeutic benefit and low toxicity, targeting CEACAM6 may emerge as a viable option for duodenal polyposis control in FAP.